Institute for Social Research, University of Michigan, Ann Arbor, MI 48104, USA.
JAMA. 2011 Oct 5;306(13):1447-53. doi: 10.1001/jama.2011.1410.
It is unclear if advance directives (living wills) are associated with end-of-life expenditures and treatments.
To examine regional variation in the associations between treatment-limiting advance directive use, end-of-life Medicare expenditures, and use of palliative and intensive treatments.
DESIGN, SETTING, AND PATIENTS: Prospectively collected survey data from the Health and Retirement Study for 3302 Medicare beneficiaries who died between 1998 and 2007 linked to Medicare claims and the National Death Index. Multivariable regression models examined associations between advance directives, end-of-life Medicare expenditures, and treatments by level of Medicare spending in the decedent's hospital referral region.
Medicare expenditures, life-sustaining treatments, hospice care, and in-hospital death over the last 6 months of life.
Advance directives specifying limits in care were associated with lower spending in hospital referral regions with high average levels of end-of-life expenditures (-$5585 per decedent; 95% CI, -$10,903 to -$267), but there was no difference in spending in hospital referral regions with low or medium levels of end-of-life expenditures. Directives were associated with lower adjusted probabilities of in-hospital death in high- and medium-spending regions (-9.8%; 95% CI, -16% to -3% in high-spending regions; -5.3%; 95% CI, -10% to -0.4% in medium-spending regions). Advance directives were associated with higher adjusted probabilities of hospice use in high- and medium-spending regions (17%; 95% CI, 11% to 23% in high-spending regions, 11%; 95% CI, 6% to 16% in medium-spending regions), but not in low-spending regions.
Advance directives specifying limitations in end-of-life care were associated with significantly lower levels of Medicare spending, lower likelihood of in-hospital death, and higher use of hospice care in regions characterized by higher levels of end-of-life spending.
目前尚不清楚预先指示(生前遗嘱)是否与临终支出和治疗有关。
研究治疗限制型预先指示使用、临终医疗保险支出以及姑息治疗和强化治疗使用之间的关联在区域上的差异。
设计、地点和患者:前瞻性收集了 1998 年至 2007 年间在医疗保险和国家死亡指数中死亡的 3302 名医疗保险受益人的健康与退休研究调查数据,并与医疗保险索赔相关联。多变量回归模型根据死者所在医院转介区域的医疗保险支出水平,检查了预先指示、临终医疗保险支出和治疗之间的关联。
临终前 6 个月的医疗保险支出、维持生命的治疗、临终关怀和院内死亡。
在临终支出平均水平较高的医院转介区域,指定治疗限制的预先指示与较低的支出相关(每个死者减少 5585 美元;95%置信区间,-10903 美元至-267 美元),但在临终支出水平较低或中等的医院转介区域,支出没有差异。在高支出和中等支出区域,指示与院内死亡的调整后概率降低相关(高支出区域为-9.8%;95%置信区间,-16%至-3%;中等支出区域为-5.3%;95%置信区间,-10%至-0.4%)。在高支出和中等支出区域,预先指示与调整后使用临终关怀的概率增加相关(高支出区域为 17%;95%置信区间,11%至 23%;中等支出区域为 11%;95%置信区间,6%至 16%),但在低支出区域则不然。
在临终关怀中指定限制的预先指示与医疗保险支出水平显著降低、院内死亡可能性降低以及在临终支出水平较高的地区使用临终关怀的可能性增加相关。